- Home
- SJT vs IPHA Comparison
SJT vs IPHA Comparison
Compare SJT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | IPHA |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.8M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SJT | IPHA |
|---|---|---|
| Price | $5.78 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 200.1K | 26.6K |
| Earning Date | 11-13-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,557.00 | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.77 | $1.63 |
| 52 Week High | $7.22 | $2.63 |
Technical Indicators
Market Signals| Indicator | SJT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 46.43 |
| Support Level | $5.67 | $1.72 |
| Resistance Level | $6.09 | $1.86 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 60.00 | 39.39 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.